You don't need HR's permission to start medical weight loss treatment, but you do need their support if you want the cost covered or reimbursed as part of your benefits package — and that requires a pitch built on numbers, not wellness language.
- Medical weight loss as an employee benefit lands best framed as a flat-fee membership, not an open drug line — bring the $299/month structure to HR.
- Employers who reimburse GLP-1 prescriptions directly face dose-escalation cost creep; a zero-markup pharmacy model removes that variable.
- Propose a 5-10 person pilot before asking for a company-wide rollout — smaller asks clear budget review faster.
- Bring quarterly Biomarker Audit data (ApoB, HbA1c, hs-CRP) as the clinical case, not weight-loss anecdotes alone.
- Time the pitch six to eight weeks before the benefits renewal or open enrollment deadline, not after it.
Why this matters
Most employees who want their company to help with medical weight loss show up to the conversation with a screenshot of a GLP-1 price tag and a request to "cover Ozempic." That pitch dies in the first five minutes, because it asks the employer to underwrite an open-ended prescription with no cost ceiling.
A better pitch treats medical weight loss as an employee benefit the same way you'd pitch any other line item: fixed cost, defined scope, clear clinical oversight, and a start date. Employers can say yes to a flat $299/month membership. They can't say yes to an unpriced medication category that escalates every time a dose goes up.
The distinction matters more in 2026 than it did two years ago. Branded GLP-1 costs and dose-escalation billing have made a lot of HR teams wary of any pitch that smells like an open checkbook. A structured, capped-cost model is the version that gets approved.
Employers can say yes to a flat $299/month membership. They can't say yes to an unpriced medication category that escalates every time a dose goes up.
What you'll need before the meeting
- A specific ask — reimbursement, stipend, or listing as a preferred benefit vendor. Pick one.
- The cost numbers — $299/month, $598 for the first two months, then month-to-month with no term commitment after that.
- The right decision-maker — HR director, benefits broker, or the founder directly if you're under 50 employees.
- A renewal-cycle deadline — most benefits budgets lock 60-90 days before the plan year starts.
- A one-page summary, not a slide deck. Decision-makers read one page. They skim ten.
- An informal headcount of coworkers who'd actually use it, if you can get it without turning into a petition.
The steps
1. Name the cost problem in the employer's language
HR doesn't think in terms of "weight loss support." They think in terms of claims trend, absenteeism, and premium renewal numbers. Frame the ask as risk management: cardiometabolic conditions — elevated A1c, high ApoB, uncontrolled blood pressure — are recurring drivers of the claims that spike a company's renewal rate. Common mistake: opening with a personal health story instead of a cost framing. Save the personal story for question two.
2. Bring the flat-fee number, not a percentage
Vague asks get vague answers. Come in with the exact structure: a $299/month membership, a $598 charge for the first two months, then cancel-anytime billing. Point out that how much a direct primary care membership costs is a fixed number employers can budget against, unlike a drug benefit that changes as a dose titrates. Common mistake: quoting a "starting at" price without the full commitment structure — HR will ask, so have the answer ready before they do.
3. Separate the membership from your group health plan entirely
This is the detail that unlocks approval faster than anything else: the membership doesn't run through the company's insurance carrier, doesn't touch the group plan's claims experience, and doesn't require the employer to see any clinical detail. It's a direct-pay relationship between the employee and the clinical team. Why it matters: HR teams are far more comfortable approving a stipend for an outside service than adding a new drug category to a self-funded plan's risk pool.
4. Anchor the clinical credibility
Employers hesitate on anything that sounds like a weight-loss fad. Counter that directly: clinical care is delivered by board-certified physicians licensed in all 50 states, working under GoodLife Health's clinical protocols, and every patient gets a comprehensive Biomarker Audit — ApoB, Lp(a), hs-CRP, HbA1c, full hormone and thyroid panels — every 90 days before any prescription decision is made. That's a lab-driven model, not a self-serve prescription pad. Common mistake: leading with the drug name (Ozempic, Zepbound) instead of the clinical oversight behind it — the oversight is what gets legal and HR comfortable.
Every patient gets a comprehensive Biomarker Audit — ApoB, Lp(a), hs-CRP, HbA1c, full hormone and thyroid panels — every 90 days before any prescription decision is made. That's a lab-driven model, not a self-serve prescription pad.
5. Propose a pilot cohort, not a company-wide rollout
Full-benefit asks get tabled. Pilot asks get answered. Suggest a 90-day pilot with 5 to 10 interested employees, reimbursed or stipended at the $299/month rate, with a simple check-in at the end of the quarter. Why it matters: a pilot has a natural off-ramp if it doesn't work, which removes the biggest reason a benefits committee stalls a decision.
6. Pre-empt the objections before HR raises them
Have answers ready for: "Does this replace our health insurance?" (No — it's a supplement, and direct primary care for small business owners works alongside an existing group plan, not instead of it). "What about compounded semaglutide safety concerns?" (Not applicable — only branded, FDA-approved GLP-1s are prescribed: Wegovy, Zepbound, Ozempic, Mounjaro, and oral Foundayo, never compounded). Common mistake: waiting for HR to ask these questions instead of answering them in your one-pager.
Only branded, FDA-approved GLP-1s are prescribed: Wegovy, Zepbound, Ozempic, Mounjaro, and oral Foundayo — never compounded semaglutide.
7. Put the ask in writing with a decision date
Verbal pitches get forgotten. Follow the meeting with a two-paragraph email: the ask, the cost, the pilot size, and a specific date you'd like a decision by. Why it matters: a written ask with a deadline moves through approval chains; an open-ended verbal request sits in someone's inbox until the next renewal cycle.
Troubleshooting the pitch
- HR says GLP-1s are already covered under the medical plan. Point out that insurance-covered GLP-1 access usually requires a type 2 diabetes diagnosis and prior authorization; this membership covers weight management directly without that gate, and it doesn't touch the group plan's claims.
- Legal worries about employer visibility into medications. Clarify the employer never sees a diagnosis or prescription — the clinical relationship stays between the employee and the clinician. The employer's only role is covering or reimbursing the membership fee.
- The founder says budget is frozen until next fiscal year. Ask for a smaller ask: a stipend for a 3-person pilot funded out of an existing wellness or professional-development line, not a new budget category.
- Someone raises "is this just Ozempic with markup?" No — medications are billed by the pharmacy at pharmacy cost, with zero markup and no dose-escalation fee. The $299 doesn't change when a prescription changes.
- Employees worry this replaces their doctor. It doesn't. It adds a concierge-style direct primary care relationship on top of existing coverage, with quarterly labs guiding treatment.
- HR asks "why not just negotiate a group rate?" Be honest: there's no group-rate structure to point to here. The pitch is a stipend or reimbursement of the existing individual membership, not a negotiated corporate contract.
Tools and resources
- A one-page cost comparison: $299/month flat vs. estimated per-dose cost creep under a typical insurance-covered GLP-1 benefit.
- The how to pitch concierge medicine as an employer benefit guide, for framing the primary-care side of the same ask.
- A short internal poll (five people, informal) showing real interest before the meeting.
- Your company's benefits renewal calendar — know the exact lockout date before you schedule the pitch.
What to do next
Once you have buy-in, or even a maybe, the next step is understanding what the first 90 days actually look like clinically — labs first, then a prescribing decision, not the other way around. That's worth walking through with HR too, since it's the strongest evidence this isn't a rubber-stamp prescription service.
Clinical trial benchmarks
Trial figures, not guarantees
| Trial | Medication | Result |
|---|---|---|
| STEP-1 | Semaglutide | Roughly 15% average weight loss at 68 weeks |
| SURMOUNT-1 | Tirzepatide | Up to roughly 22.5% |
FAQ
What is medical weight loss as an employee benefit?
It's an employer covering or reimbursing an employee's membership in a physician-supervised weight loss program, typically structured as a flat monthly fee rather than a drug reimbursement line. In 2026, the most common structure is a stipend or preferred-vendor listing rather than a change to the group health plan.
How much does it cost an employer to offer this?
A membership like GoodLife Health's runs $299 a month per employee after a $598 charge for the first two months, with no long-term contract after that. Employers aren't negotiating a group rate here — they're deciding whether to stipend or reimburse the individual membership fee.
Does this require changing our group health insurance plan?
No. The membership is a direct-pay relationship between the employee and the clinical team and does not run through the employer's group insurance carrier or affect the plan's claims experience.
What GLP-1 medications are actually prescribed?
Only branded, FDA-approved GLP-1s: Wegovy, Zepbound, Ozempic, Mounjaro, and oral Foundayo. Compounded semaglutide or tirzepatide is never prescribed, under any circumstance.
Will my employer see my diagnosis or prescriptions?
No. The clinical relationship, including diagnoses and medications, stays between you and your clinician. The employer's involvement is limited to covering or reimbursing the membership cost.
How do I propose a smaller version of this instead of a full rollout?
Ask for a 90-day pilot with five to ten interested employees at the standard $299/month rate, with a simple check-in at the end of the quarter before any decision on expanding it.
How long before results show up to justify the cost?
Clinical trial data offers a benchmark: the STEP-1 trial showed roughly 15% average weight loss on semaglutide at 68 weeks, and SURMOUNT-1 showed up to roughly 22.5% on tirzepatide, though individual results vary and these are trial figures, not guarantees.
What if our company already has a wellness stipend?
Ask HR to route the membership reimbursement through the existing stipend structure instead of requesting a new benefit category. It's an easier approval since the budget line already exists.
One last thing
The detail most employees leave out of the pitch is the one HR actually cares about most: the quarterly Biomarker Audit isn't just for weight loss. ApoB, Lp(a), and hs-CRP catch cardiovascular risk early, and HbA1c catches metabolic drift before it becomes a diabetes diagnosis. For a self-funded employer, that's the argument that turns a nice-to-have into a line item that reduces future claims risk, not just a perk that makes a benefits packet look generous.
Related guides
- How to pitch concierge medicine as an employer benefit
- How to find a weight loss doctor who prescribes GLP-1s
- Direct primary care for small business owners
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/